Consistent with our results, a 12-month retrospective study5 of 474 women with breast cancer treated with CDK4/6 inhibitors reported a decline in eGFR among patients treated for the entire 12-month duration, although no patients reached the composite outcome of ESKD, eGFR<10, or sustained 40% decline in eGFR. This evidence concerns the gene CDK4 and breast carcinoma.